# Packet 01.5 — Discovery Pass 61

STATUS: DISCOVERY IN PROGRESS
PHASE: PROBLEM FINDING ONLY
ROUTING: NOT STARTED
COUNT MODE: NATURAL YIELD
DATE: 2026-06-14

This pass looks for pharmaceutical and medical-product lifecycle failure involving discovery, formulation, clinical development, manufacturing scale-up, regulatory approval, medical-device lifecycle, recall, post-market field correction, and end-of-life.

APPLICABILITY GATE: These are conditional future candidates, not proof of current app defects. They become applicable only if the project stores, interprets, recommends, coordinates, routes, or governs pharmaceutical, clinical-development, medical-device, manufacturing, regulatory, recall, safety, or end-of-life information, decisions, or services.

## Provisional records

### DRUGDISC-001 — Discovery program optimizes a measurable surrogate rather than the real clinical outcome

Biomarkers, model systems, screening scores, and short experiments may favor candidates that perform well in the test but not in patients.

HARM: resources and confidence accumulate around a mechanism that does not produce meaningful benefit.

OVERLAP TO CHECK: MEAS-004, MODEL-006.

### DRUGDISC-002 — Preclinical evidence underrepresents human diversity and comorbidity

Age, sex, genetics, organ function, environment, diet, and concurrent illness may differ from the models used.

HARM: a candidate appears safe and effective before entering a population unlike the evidence base.

OVERLAP TO CHECK: GENOME-002, DESIGN-004.

### DRUGDISC-003 — Negative findings disappear while positive findings shape development

Publication, portfolio pressure, sunk cost, selective analysis, and internal incentives may suppress weak or contradictory evidence.

HARM: development proceeds on a biased picture of benefit and risk.

OVERLAP TO CHECK: PUB-004, INCENT-001.

### DRUGDISC-004 — Intellectual-property strategy delays or narrows safety collaboration

Competitive secrecy, licensing, ownership, and publication control may restrict sharing of compounds, methods, failures, and adverse mechanisms.

HARM: duplicated mistakes and preventable risk persist across organizations.

OVERLAP TO CHECK: OWN-001, SAFEGUARD-002.

### DRUGDISC-005 — Early target choice creates downstream dependence that becomes hard to reverse

Assays, chemistry, contracts, teams, trials, manufacturing, and investor expectations may all align around the initial hypothesis.

HARM: later contradictory evidence is discounted because the whole program depends on continuation.

OVERLAP TO CHECK: LOCKIN-001, TRUST-004.

### FORMUL-001 — Formulation changes exposure while being treated as the same medicine

Release rate, particle size, excipients, route, device, food effects, storage, and patient handling may change absorption and tolerability.

HARM: equivalence in name hides clinically important difference in use and effect.

OVERLAP TO CHECK: DISPENSE-004, FORM-001.

### FORMUL-002 — Excipient risk is assessed as secondary to the active ingredient

Allergy, intolerance, age, pregnancy, organ disease, route, cumulative exposure, and interactions may make inactive components consequential.

HARM: a clinically appropriate active drug causes preventable harm through the formulation.

OVERLAP TO CHECK: ALLERGEN-001, PRESCRIBE-001.

### FORMUL-003 — Stability testing does not represent real transport and use conditions

Temperature cycling, humidity, light, vibration, opening, dilution, device transfer, and repeated handling may differ from controlled storage.

HARM: a product remains within labeled time while potency, sterility, or performance has degraded.

OVERLAP TO CHECK: COLD-001, DISPENSE-005.

### FORMUL-004 — Palatability and usability changes adherence differently across populations

Taste, volume, swallowing, injection burden, device force, sensory experience, and packaging may affect children, older adults, and disabled users differently.

HARM: a technically effective product fails because people cannot use it consistently or safely.

OVERLAP TO CHECK: ADHERE-001, BLDACC-001.

### CLINDEV-001 — Trial population excludes the people most likely to use the product

Comorbidity, pregnancy, disability, age, language, unstable housing, polypharmacy, and limited access may be excluded.

HARM: approval evidence does not represent real-world users and risks.

OVERLAP TO CHECK: DESIGN-004, PHARMVIG-003.

### CLINDEV-002 — Trial endpoint captures short-term response while missing delayed harm

Follow-up may be too short for recurrence, cumulative toxicity, dependence, device wear, cancer, fertility, or developmental effects.

HARM: benefit is established before the full risk window is observable.

OVERLAP TO CHECK: STEWARD-003, PHARMVIG-001.

### CLINDEV-003 — Protocol amendments change the question after results begin emerging

Eligibility, dose, endpoint, analysis, visit timing, and sample size may shift during development.

HARM: evidence appears coherent even though the study no longer answers one stable question.

OVERLAP TO CHECK: VER-001, CASEDEF-001.

### CLINDEV-004 — Site quality varies while pooled results assume one trial

Staffing, training, recruitment, measurement, documentation, participant support, and local practice may differ by site.

HARM: pooled averages hide unreliable or systematically different local evidence.

OVERLAP TO CHECK: LABNET-003, COLLAB-004.

### CLINDEV-005 — Participant retention strategy conceals treatment burden

Payments, travel support, repeated persuasion, investigator authority, and fear of losing care may keep people enrolled despite distress.

HARM: continued participation is mistaken for acceptability and voluntary consent.

OVERLAP TO CHECK: CONSENT-001, WKAUTH-001.

### CLINDEV-006 — Comparator choice exaggerates apparent benefit

Placebo, outdated care, weak dose, unsuitable population, or noninferiority margin may make the new product look stronger than relevant alternatives.

HARM: approval and adoption are based on a comparison that does not reflect real clinical choice.

OVERLAP TO CHECK: FRAME-002, MEAS-002.

### REGAPP-001 — Regulatory dossier integrates evidence generated under incompatible versions

Formulation, device, software, manufacturing process, protocol, and population may change across development.

HARM: approval treats evidence as if it supports one stable product configuration.

OVERLAP TO CHECK: MIXVER-001, AIRCERT-001.

### REGAPP-002 — Review clock pressures uncertainty into a binary approval decision

Incomplete follow-up, emerging signals, missing subgroups, and manufacturing questions may remain unresolved at the deadline.

HARM: administrative timing converts uncertainty into authorization or denial without a durable evidence plan.

OVERLAP TO CHECK: DEAD-001, FRAME-001.

### REGAPP-003 — Conditional approval expands use faster than confirmatory evidence arrives

Market uptake, reimbursement, guidelines, and patient expectations may grow before required studies finish.

HARM: temporary evidence status becomes de facto permanent adoption.

OVERLAP TO CHECK: EXP-006, MEDINT-004.

### REGAPP-004 — Regulatory reliance imports another authority’s blind spots

Different populations, standards, inspections, data access, healthcare systems, and legal powers may limit transferability.

HARM: efficient reliance reproduces unexamined assumptions and missing evidence.

OVERLAP TO CHECK: JUR-001, PHBORDER-001.

### SCALEUP-001 — Manufacturing scale-up changes mixing, heat, contamination, and material behavior

Equipment geometry, hold time, transfer, cleaning, shear, concentration, and operator interaction may differ from development scale.

HARM: the commercial process produces a product unlike the validated small-scale material.

OVERLAP TO CHECK: REACT-001, QUALITY-003.

### SCALEUP-002 — Process validation proves nominal runs but not edge conditions

Startup, shutdown, maintenance, raw-material variation, staffing, environmental change, and equipment aging may remain underrepresented.

HARM: a validated process fails during ordinary non-nominal operation.

OVERLAP TO CHECK: TEST-005, SHUTDOWN-004.

### SCALEUP-003 — Supplier change alters product performance without obvious specification failure

Source material, impurities, packaging, sterilization, transport, and analytical methods may differ while meeting broad limits.

HARM: a compliant input changes safety, stability, or effectiveness.

OVERLAP TO CHECK: SUPPLY-001, REACT-002.

### SCALEUP-004 — Batch release data are complete while the physical batch history is not

Rework, deviation, equipment state, hold time, operator intervention, and sampling limits may be compressed into approved records.

HARM: release status hides a process history that should change risk judgment.

OVERLAP TO CHECK: GOVREC-001, TRACEPROD-002.

### SCALEUP-005 — Capacity shortage creates pressure to weaken deviation and rejection decisions

Scarcity, contracts, launch commitments, public need, and limited alternatives may influence quality disposition.

HARM: products enter use because supply pressure outweighs unresolved quality evidence.

OVERLAP TO CHECK: SHORTMED-001, INCENT-001.

### MEDDEV-001 — Device performance depends on software, accessories, consumables, and user setup not tested as one system

Compatible parts, versions, network settings, calibration, batteries, and workflow may vary in the field.

HARM: a certified device fails through dependencies outside the tested configuration.

OVERLAP TO CHECK: AIRCERT-001, FEATURE-001.

### MEDDEV-002 — Usability testing excludes stressed, fatigued, disabled, or unfamiliar users

Clinicians, patients, caregivers, and responders may use the device under time pressure, poor lighting, noise, gloves, or limited training.

HARM: ordinary human conditions create setup, interpretation, or control errors.

OVERLAP TO CHECK: UI-003, STRESS-004.

### MEDDEV-003 — Device alarm burden hides the critical event

Frequent nonactionable alerts, threshold differences, disconnected sensors, and alarm escalation may overwhelm users.

HARM: the one dangerous condition is missed inside routine alarm noise.

OVERLAP TO CHECK: ALERT-001, PRESCRIBE-004.

### MEDDEV-004 — Remote update changes clinical behavior after deployment

Algorithms, thresholds, interfaces, connectivity, cybersecurity, and compatibility may change without equivalent local revalidation.

HARM: field performance diverges from training, approval evidence, and care protocols.

OVERLAP TO CHECK: REMOTE-003, BATSTORE-004.

### MEDDEV-005 — Maintenance history does not follow leased, shared, or transferred equipment

Calibration, repair, cleaning, software, damage, recall, and usage may fragment across owners and sites.

HARM: the receiving user cannot know the true condition or safety status.

OVERLAP TO CHECK: AIRMAINT-004, TRACEPROD-003.

### RECALL-001 — Recall scope is defined by shipment records that do not represent current location

Resale, transfer, repackaging, home use, informal distribution, and data errors may break traceability.

HARM: affected products remain in use because the recall cannot reach them.

OVERLAP TO CHECK: TRACE-001, MEDFAKE-002.

### RECALL-002 — Recall communication identifies the product but not the immediate clinical consequence

Patients and clinicians may not know whether to stop, substitute, monitor, return, or continue temporarily.

HARM: a safety notice creates abrupt treatment interruption or continued hazardous use.

OVERLAP TO CHECK: PHARMVIG-004, COMMS-001.

### RECALL-003 — Replacement supply is insufficient for the recalled population

Manufacturing capacity, alternatives, compatibility, training, and distribution may lag the recall.

HARM: removing one risk creates shortage, withdrawal, delayed procedure, or unsafe substitution.

OVERLAP TO CHECK: SHORTMED-001, ALLOC-001.

### RECALL-004 — Recall closure measures returned units rather than residual exposure

Unreachable users, already consumed doses, implanted devices, secondary markets, and long-term monitoring may remain.

HARM: administrative completion is mistaken for elimination of patient risk.

OVERLAP TO CHECK: POST-003, PERSIST-001.

### FIELDCORR-001 — Field correction depends on local staff recognizing that their configuration is affected

Versions, accessories, workflows, serials, and integrations may differ.

HARM: a correction is issued but not applied where the actual unsafe condition exists.

OVERLAP TO CHECK: MIXVER-001, SUPPORT-001.

### FIELDCORR-002 — Software correction solves one failure while changing another clinical behavior

Thresholds, timing, display, interoperability, performance, and user expectations may shift.

HARM: a safety update creates a new unrecognized treatment or diagnosis risk.

OVERLAP TO CHECK: FEATURE-001, CONTAIN-001.

### FIELDCORR-003 — Post-market signal is dismissed because each complaint appears individually explainable

Rare events, user error, comorbidity, environment, and incomplete reports may obscure a common pattern.

HARM: distributed weak signals are not combined before severe harm repeats.

OVERLAP TO CHECK: PHARMVIG-001, INCDET-002.

### FIELDCORR-004 — Reporting channels favor institutions over patients and caregivers

Consumers may lack terminology, serial data, clinical records, time, language, and confidence to report effectively.

HARM: safety learning underweights harms experienced outside well-resourced systems.

OVERLAP TO CHECK: PHSURV-001, SUPPORT-003.

### MEDEND-001 — Product end-of-life removes service before clinical dependence ends

Software support, consumables, batteries, calibration, repair, and cloud services may stop while devices remain implanted or essential.

HARM: vendor retirement converts functioning care into unsupported risk.

OVERLAP TO CHECK: DEP-005, CARETECH-001.

### MEDEND-002 — Disposal preserves biological, chemical, radiological, battery, and privacy hazards

Used products may contain medicines, sharps, patient data, contaminated material, electronics, and stored energy.

HARM: clinical benefit becomes downstream worker, community, and environmental exposure.

OVERLAP TO CHECK: MEDWASTE-001, BATSTORE-005.

### MEDEND-003 — Device replacement transfers data and settings incompletely

History, calibration, personalization, therapy parameters, alerts, and caregiver access may not migrate safely.

HARM: replacement intended to restore support loses the configuration that made treatment effective.

OVERLAP TO CHECK: MIG-001, CARETRANS-005.

## Pass 61 result

Natural-yield provisional records: 40
Routing decisions made: 0
Records closed: 0
Deduplication required later: Yes
Discovery saturation: NOT REACHED

Corrected working total:
- Preserved baseline: 122
- Prior actual provisional headings: 2385
- Pass 61 natural-yield provisional: 40
- Current actual provisional headings: 2425
- Current combined working total: 2547

NEXT DISCOVERY PASS:
Natural hazards and disaster-management systems, including earthquake, tsunami, flood, severe storm, heat, drought, volcanic activity, landslide, dam failure, warning governance, mass evacuation, sheltering, mutual aid, and long-term recovery.

END PACKET 01.5 — DISCOVERY PASS 61
